The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 19, 2006
Filed:
Jul. 15, 2003
Jui-lin Chen, Taipei, TW;
Yuchi Hwang, Taipei, TW;
Min-pey Ding, Taipei, TW;
Wen-pi Chu, Taoyuan, TW;
Shu-ching Wang, Taipei, TW;
Kuei-ling Belinda Chen, Taipei, TW;
Wan-lin Yao, Taichung, TW;
Kuang-den Chen, Taipei, TW;
Ding-shinn Chen, Taipei, TW;
Pei-jer Chen, Taipei, TW;
Ming-yang Lai, Taipei, TW;
Jui-Lin Chen, Taipei, TW;
Yuchi Hwang, Taipei, TW;
Min-Pey Ding, Taipei, TW;
Wen-Pi Chu, Taoyuan, TW;
Shu-Ching Wang, Taipei, TW;
Kuei-Ling Belinda Chen, Taipei, TW;
Wan-Lin Yao, Taichung, TW;
Kuang-Den Chen, Taipei, TW;
Ding-Shinn Chen, Taipei, TW;
Pei-Jer Chen, Taipei, TW;
Ming-Yang Lai, Taipei, TW;
Vita Genomics, Inc., Taipei, TW;
Abstract
It is provided isolated polynucleotides that include sequences from genomic region around the gene CD 81. The polynucleotides include polymorphisms associated with treatment response of HCV patients to interferon-α and ribavirin combined therapy and are useful as the probes in screening for patients who will response to interferon-α and ribavirin combined therapy. It is further provided linkage disequilibrium structure of the CD81 gene and haplotype information within a particular LD block, which can be used for prediction of the treatment outcome of the interferon-α and ribavirin combined therapy on HCV patients.